All stock lists
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.91+0.09 (+4.67%)
Market cap
$848M
Insider Score
Health Score
Analyst consensus
Listed since
Apr 7, 2000
Website
Insider Score
56/ 100
LXRX Insider Score
Bullish1 qualifying trade · 1 insider · $50.00K bought in the last 90 days
LXRX analyst forecast
LXRX analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
LXRX 12-month price target
No published price targets in the last 12 months.
LXRX ratings mix, last 12 months
Buy Hold Sell
Best analysts covering LXRX
- Citigroup50%success rate · +9.9% avg return · 4 calls
- HC Wainwright & Co.43%success rate · +48.1% avg return · 21 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
LXRX analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Citigroup | Buy | — | — | Reiterated | 2026-11-09 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-05-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-23 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-03-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-09-02 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-08-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-06-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-28 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2025-03-07 |
| — | Needham | Hold | — | — | Reiterated | 2025-03-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-07 |
| — | Leerink Partners | Market Perform | — | — | Downgraded | 2025-03-04 |
| — | Needham | Hold | — | — | Reiterated | 2025-03-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-29 |
| — | Needham | Hold | — | — | Reiterated | 2025-01-29 |
| — | Needham | Hold | — | — | Reiterated | 2024-12-23 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-30 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-23 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-17 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-09-27 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-09-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-09-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-21 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-02 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-07-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-06-24 |
| — | Citigroup | Buy | — | — | Reiterated | 2023-05-31 |
| — | Needham | Hold | — | — | Reiterated | 2023-05-30 |
| — | Jefferies | Hold | — | — | Reiterated | 2023-03-07 |
| — | Citigroup | Buy | — | — | Reiterated | 2022-11-22 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2022-08-12 |
| — | Citigroup | Buy | — | — | Reiterated | 2022-07-01 |
| — | JP Morgan | Neutral | — | — | Upgraded | 2021-01-29 |
| — | Wedbush | Neutral | — | — | Downgraded | 2021-01-29 |
| — | Citigroup | Buy | — | — | Upgraded | 2020-12-08 |
| — | Gabelli & Co. | Buy | — | — | Upgraded | 2020-11-18 |
| — | Citigroup | Neutral | — | — | Reiterated | 2020-04-28 |
| — | Gabelli & Co. | Hold | — | — | Downgraded | 2019-12-11 |
| — | Citigroup | Neutral | — | — | Downgraded | 2019-11-08 |
| — | Gabelli & Co. | Buy | — | — | Upgraded | 2019-09-11 |
| — | Citigroup | Buy | — | — | Reiterated | 2019-07-30 |
| — | Stifel Nicolaus | Hold | — | — | Downgraded | 2019-07-29 |
| — | Stifel | Hold | — | — | Downgraded | 2019-07-29 |
| — | Gabelli & Co. | Hold | — | — | Upgraded | 2019-03-25 |
| — | Gabelli & Co. | Sell | — | — | Downgraded | 2019-03-14 |
| — | Citigroup | Buy | — | — | Reiterated | 2018-11-02 |
| — | Stifel Nicolaus | Buy | — | — | Reiterated | 2018-07-31 |
| — | Stifel | Buy | — | — | Reiterated | 2018-07-31 |
| — | Citigroup | Buy | — | — | Reiterated | 2018-05-04 |
| — | Stifel Nicolaus | Buy | — | — | Reiterated | 2018-05-04 |
| — | Stifel | Buy | — | — | Reiterated | 2018-05-04 |
| — | Wedbush | Outperform | — | — | Reiterated | 2018-04-16 |
| — | JP Morgan | Underweight | — | — | Downgraded | 2018-02-14 |
LXRX earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-05 | -0.07 | -0.04 | $3.1M | $5.5M |
| 2026-05-07 | -0.04 | -0.00 | $9.8M | $21.1M |
| 2026-08-06 | -0.05 | -0.06 | $4.0M | $692K |
| 2026-11-05 | -0.06 | -0.03 | $4.1M | $11.3M |
| 2027-03-04Upcoming | -0.05 | — | $11.2M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.